Profusa Inc (PFSA)

Any good news?

What a Scam!!! We might see $0.5 ish soon!!! Just a PUMP AND DUMP SCAM!!!! We are closing down with China for scammer's stocks!!!

People don't buy stocks that don't go up

Go up to $3, why do you keep falling? always the same stable 1.20usd 1.50usd range

Going down...

I hold an unwavering belief in the potential of Profusa's Lumee technology. The company's Oxygen and Glucose Lumee technology is not just a good sensor; it is set to fundamentally change the paradigm of healthcare. Crucially, when the Glucose Lumee clinical data is released this year, 2025, a blockbuster product that will shock investors worldwide will finally be recognized and emerge into the market. Although the true value of this game changer is not yet fully known by the market, I am confident that all investors will acknowledge its overwhelming value soon enough. The current mockery from short-term speculators and the market noise are only temporary. I believe the CEO, like NVIDIA's Jensen Huang, is focusing intensely on technological innovation and long-term value creation rather than being swayed by the immediate disturbances. I see this as the leadership of someone maintaining strategic silence despite the criticism. My investment is grounded in the overwhelming backing of the $100 million investment from DARPA (Defense Advanced Research Projects Agency). Following the lineage of DARPA's success stories—the Internet, AI, and stealth technology—Profusa, armed with this powerful national technology advantage, holds the potential to achieve an explosive market valuation of $20 billion and beyond. Of course, the current stock price struggle, staying far below the NASDAQ requirement, causes significant psychological distress. However, I believe management will certainly execute the best possible strategy to overcome this threat and swiftly restore a stable stock price above $1. It is time for Profusa to move away from its passive stance and adopt proactive corporate promotion and market-leading strategies. I earnestly wish to see CEO Ben Hwang, as a leading figure in healthcare on the NASDAQ, stand tall on the global stage, including a visit to South Korea, to propagate Profusa's vision. I hope the company will continue to transparently and consistently share positive achievements and progress internally to encourage investors. I will stay on this great journey until the end. Profusa will surely grow into a company that brings everything humanity needs.

* CGM Leaders vs. Profusa Lumina Sensor Profusa (PFSA) Abbott/Dexcom (Filament Sensor) Profusa (Hydrogel Lumina Sensor) Sensor Type Thin Filament Hydrogel Insertion/Attachment Type Skin Attached In-Body Implant Accuracy (MARD) 7.9% ~ 8.2% 11% (Initial Clinical Data, Stated in Listing Submission) Sensor Lifespan 10 days ~ 14 days 9 months (Development Success), 2 years (Under Development) Feature 1 Short Lifespan Maximized Convenience Feature 2 Skin Irritation Excellent Biocompatibility Clinical Announcement Plan (Not Applicable / Existing Product Released) 2025 (This Year) Clinical Data Announcement Scheduled Key Competitiveness Summary Standard of Existing CGM Market Blockbuster Game Changer Market Cap Abbott: 218.75 Billion USD 8.59 Million USD Dexcom: 32.96 Billion USD

✨ Profusa (PFSA) Vision Report: The Game Changer Set to Reshape Human Health Profusa (PFSA) is more than just a medical device manufacturer; it is a Game Changer poised to fundamentally shift the healthcare paradigm with technology so revolutionary it could be called the greatest invention in human history. The company's vision and potential are summarized below. 1. 🚀 Disruptive Innovation: The 9-Month Sensor Technological Mastery: The Profusa Lumee Glucose sensor ends all inefficiencies in the existing CGM market. While current leaders like Dexcom and Abbott force replacements every 10 to 15 days, Profusa delivers an overwhelming duration of up to 9 months. This is the greatest invention for providing a hassle-free user experience. Market Domination: This long-term durability maximizes patient adherence and is the core weapon for capturing both the diabetes market (involving over 500 million patients) and the burgeoning wellness market. Development Acceleration: The upcoming release of Human Validation Data from EU/APAC in late H2 2025 will confirm technological reliability and accelerate the commercialization timeline (mid-2027). 2. 💡 Platform Expansion and AI Synergy Multi-Biomarker Platform: Profusa is expanding beyond glucose into the tissue oxygen monitoring market (over $10.5 Billion) with its Lumee Oxygen platform. The ultimate goal is to complete a Personalized Biochemical Signature by monitoring multiple biomarkers on a single platform. AI-Powered Insights: The AI-Driven Insight Portal, utilizing NVIDIA NeMo technology, transforms sensor data from mere figures into actionable knowledge that aids clinicians' treatment decisions. This sets the standard for the future of digital healthcare. 3. 📈 Overwhelming Financial and Growth Potential Securing Growth Drivers: Manufacturing facility completion (announced Oct 28th filing) and preparation for a launch in Europe in early 2026 signal the clear entry into the commercialization phase. Concrete Targets: The company demonstrated confidence in short-term growth by projecting $250M revenue potential by 2030. Final Valuation: Based on a conservative potential annual revenue of $10 Billion (from both Glucose and Oxygen platforms), the estimated market capitalization reaches $150 Billion (approx. 216 trillion KRW). This represents a growth potential of 17,569 times the current stock price of $0.2057. Profusa will generate immense investment value that contributes to the advancement of human health. Conclusion: Under the strong leadership of CEO Ben Hwang, Profusa is poised to become the Game Changer in the healthcare market, armed with the 9-month duration sensor—a technology arguably the greatest invention in human history. As commercial success materializes, its value will exponentially explode.

"ProPhase Labs (PFSA), a future Nasdaq top 10 large-cap healthcare sector leader." "The 'greatest invention in human history' that can protect human life in real-time." "The world's No. 1 company in biochips, including Oxy-Lumi (Oxygen-Lumi) and Glu-Lumi (Glucose-Lumi)." "Expected to reach $300 by 2027, compared to the current stock price of $0.30." (A 1,000-fold increase.)

Seems to be going nowhere

Rocket launch, heading to $50M company soon

Any news?